Curative approach for stage IV colorectal cancer with multiorgan involvement: What makes sense and what doesn't?

Polina Khrizman, Mary Frances Mulcahy

Research output: Contribution to journalReview article

Abstract

In 2009, there were almost 150,000 cases of colorectal cancer in the United States. Surgical resection of isolated metastatic pulmonary and hepatic disease has demonstrated a 10-year overall survival rate approaching 30%. The data on definitive management in multiorgan disease are not clear and are limited because of small patient cohorts, the nonrandomized nature of studies, and suboptimal chemotherapeutic agents. Current trials demonstrate that long-term survival is feasible in carefully selected patients with multiorgan metastases, including hepatic and extrahepatic involvement. Following is a review of current literature supporting the potentially curative approach to synchronous and metachronous multiorgan metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)97-107
Number of pages11
JournalCurrent Colorectal Cancer Reports
Volume6
Issue number2
DOIs
StatePublished - Apr 1 2010

Keywords

  • Colorectal cancer
  • EPIC
  • Extrahepatic disease
  • HIPEC
  • Lung and liver metastases
  • Lung and peritoneal metastases

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology
  • Hepatology

Fingerprint Dive into the research topics of 'Curative approach for stage IV colorectal cancer with multiorgan involvement: What makes sense and what doesn't?'. Together they form a unique fingerprint.

  • Cite this